LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Home・Akcijų sąrašas・Krystal Biotech Inc

Krystal Biotech Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

298.39 -2.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

297.98

Max

306.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.5M 56M
Pardavimai	9.3M 116M
P/E Sektoriaus vid.	41.829 51.415
Pelnas, tenkantis vienai akcijai	1.83
Pelno marža	48.069
Darbuotojai	295
EBITDA	16M 55M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+3.17% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.2B 9.2B
Ankstesnė atidarymo kaina	300.92
Ankstesnė uždarymo kaina	298.39

Naujienos nuotaikos

By Acuity

20%

80%

28 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

133.221 / 169.73 Palaikymas ir pasipriešinimas

Krystal Biotech Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-17 23:53; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-17 23:50; UTC

Rinkos pokalbiai

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-17 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

2026-05-17 23:07; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Transactions Part of Group's Capital Reallocation Strategy

2026-05-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Share Sale Agreements Entered With Singland Properties

2026-05-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Divestments' Aggregate Consideration of S$299M in Cash

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Fund Stake Acquisition via Internal Resources

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire Stake for $389 Million

2026-05-17 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

2026-05-16 16:27; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

2026-05-16 15:26; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

2026-05-16 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Krystal Biotech Inc Prognozė

Kainos tikslas

By TipRanks

3.17% į viršų

12 mėnesių prognozė

Vidutinis 316 USD 3.17%

Aukščiausias 378 USD

Žemiausias 284 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Krystal Biotech Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Krystal Biotech Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

133.221 / 169.73Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

28 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.